Expert Rev Clin Immunol. 2012;8(8):755-765. Different strategies can be used for managing suspected or documented candidemia, including prophylaxis, empirical or pre-emptive therapy and treatment ...

Fosmanogepix is a first-in-class antifungal treatment candidate with a novel mechanism of action. It is available in intravenous and oral formulations and has been evaluated for efficacy and safety in ...

In the decade of the 1990s, the MSG shifted its focus from the endemic mycoses and cryptococcosis to the treatment of candidemia, cryptococcosis in the HIV-infected patient, and empiric antifungal ...

The second UN High-Level Meeting on Antimicrobial Resistance on Sept 26, 2024 is expected to address the looming threat that antimicrobial resistance poses to global health and food security.1 The ...

Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in ...

Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority ...

Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix a ...

(Bloomberg) -- Alcoa Corp. will receive $1.1 billion in cash and stock in Saudi Arabian Mining Co. as part of a deal that will involve the Pittsburgh-based firm selling its stake in two metals plants ...

Candidemia is a well-known cause of in-hospital morbidity and mortality. Healthcare workers should increase their knowledge of this potentially lethal infection. Candidemia is not confined to ICUs ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...

Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix and BAL2062 -- ...